Alvotech (ALVO)
Develops and manufactures biosimilar medicines through an integrated platform and partner network.
Something off on this page? Send us feedback.
Develops and manufactures biosimilars, then uses commercial partners for market access in many countries. Several medicines are approved and marketed in multiple markets, while a broader pipeline extends the portfolio.
Develops and manufactures biosimilar medicines through an integrated platform rooted in Reykjavík. Approved products reference Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva, while a broader pipeline extends the portfolio. Commercial partners provide local market access and support launches across international markets. Broad in-house development and manufacturing capabilities are complemented by local commercial expertise.
Regulatory approvals, manufacturing and supply execution, and commercialization partnerships shape the operating model. Several candidates have progressed through FDA resubmissions after Complete Response Letters, and the company added a US second-source manufacturing agreement. In-house development and manufacturing are combined with partner-led commercialization.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 16, 2026 | UBS | Target | Target: $10 | Target: $8 |
| Sep 16, 2026 | Barclays | Upgrade | Target: $5 | Target: $8 |
| Aug 24, 2026 | Bank of America Securities | Initiate | Rating: — | |
| Aug 14, 2026 | Evercore ISI | Initiate | Rating: — | |
| Dec 8, 2025 | Barclays | Target | Target: $22 | Target: $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $142.8M · Total debt $1.45B · Total assets $1.59B · Shareholders' equity −$191.5M
- Revenue
- $105.8M
- Operating income
- −$11.8M
- Net income
- −$66.8M
No dividends on record.
| Institutions | 12.58% | 42.56M shares | |
|---|---|---|---|
| 73 holders · as of Jun 30, 2026 | |||
| Other | 87.42% | 295.66M shares | |
| remainder | |||
338.22M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Rubric Capital Management LPInstitution | 4.64% | 15.68M | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 1.26% | 4.26M | as of Jun 30, 2026 |
Bracebridge Capital, LLCInstitution | 1.19% | 4.04M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 1.09% | 3.69M | as of Jun 30, 2026 |
Farallon Capital Management LLCInstitution | 0.85% | 2.86M | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
